Drug Profile
Dresbuxelimab - Akeso Biopharma
Alternative Names: AK-119Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Akeso Biopharma
- Class Antibodies; Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies
- Mechanism of Action 5-nucleotidase inhibitors; Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Non-small cell lung cancer; Solid tumours
- No development reported COVID 2019 infections
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (IV)
- 28 Oct 2023 No recent reports of development identified for phase-I development in COVID-2019-infections(In volunteers) in New Zealand (IV, Infusion)
- 26 Jun 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Monotherapy) (IV) before June 2023 (Akeso Biopharma pipeline, June 2023)